Corestemchem Secures FDA Agreement on Phase 3b Pathway for ALS Stem Cell Therapy

The FDA reportedly viewed existing safety data from earlier trials and real-world data positively, agreeing they could be combined with new Phase 3b results in a future BLA submission.

Key Points

  • Corestemchem has received FDA meeting minutes confirming agreement on a Phase 3b trial pathway for Neuronata-R, its stem cell therapy for amyotrophic lateral sclerosis.
  • The proposed randomized, double-blind, placebo-controlled trial would use 24-week change in ALSFRS-R total score as the primary endpoint, with detailed design to follow in a Type D meeting.
  • The FDA viewed existing safety data from prior trials and real-world data positively and agreed they could be combined with new Phase 3b results in a future BLA submission.

Corestemchem has received the official FDA Type C meeting minutes confirming the agency’s agreement with a follow-up Phase 3b clinical development pathway for Neuronata-R, the company’s stem cell therapy for amyotrophic lateral sclerosis (ALS). The written record, received after last month’s meeting, makes the U.S. approval route through an additional confirmatory trial more concrete.

Neuronata-R (lenzumestrocel) is an autologous (sourced from the patient) mesenchymal stem cell therapy derived from the patient’s own bone marrow. It received conditional approval in Korea in 2014, but a Phase 3 trial completed in 2024 did not achieve statistical significance on the primary efficacy endpoint in the overall patient population. The company has since pursued an additional trial based on treatment effects observed in a subgroup of patients.

In the Type C meeting, the FDA indicated that validating the treatment effects seen in earlier studies through a new trial would be a reasonable approach. The meeting minutes confirm FDA agreement to a development path linking efficacy verification in a new Phase 3b trial to a subsequent biologics license application (BLA), rather than seeking approval on existing clinical data alone.

The Phase 3b trial is planned as a randomized, double-blind, placebo-controlled study. Corestemchem proposed the change from baseline to week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score as the primary efficacy endpoint. The FDA raised no major objections to this overall direction, and specific trial design details will be discussed in a follow-up Type D meeting.

The FDA also confirmed that safety data from prior studies could support a U.S. approval review. The agency evaluated the safety profile of Neuronata-R based on the earlier Phase 2 and Phase 3 trials and real-world data, and agreed to a plan in which Corestemchem would submit a BLA combining existing data with safety results from the new Phase 3b trial.

Corestemchem plans to conduct the Phase 3b trial in Korea, as it did for the Phase 3 study. The FDA indicated that clinical results from Korea could be used in a U.S. approval review if International Council for Harmonisation (ICH) guidelines and other requirements are met. The company intends to submit clinical trial applications to Korean and U.S. regulators simultaneously.

Detailed trial design and chemistry, manufacturing, and controls (CMC) matters remain to be resolved. The FDA had no objection to further exploring the relationship between neurofilament light chain (NfL), a marker of nerve damage, and clinical outcomes, but specific analytical methods require follow-up discussion. Comparability data for a manufacturing site change and shelf-life changes are also subject to further consultation.

The meeting minutes confirm a development direction for U.S. approval, not approval of the Phase 3b trial protocol or the product itself. Whether the new trial can overcome the failure to demonstrate efficacy in the earlier study remains a key question.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories